Clinical trial
TELICAST: Telithromycin in Acute Exacerbations of Asthma
NCT00273520 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00273520 |
|---|---|
| Title | TELICAST : Telithromycin in Acute Exacerbations of Asthma |
| Official title | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Telithromycin 800 mg (Once Daily for 10 Days) as a Supplement to the Standard of Care for Patients With Acute Exacerbations of Asthma |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Telithromycin |
| Start date | Jan 1, 2003 |
| Primary completion | Apr 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Jan 9, 2006 |
| Last update posted | Sep 15, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: